Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| (21 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | :Co-chairs: Thomas M. Link, MD | + | :Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD |
| − | : | + | :RSNA Staff Support: Susan Stanfa |
| − | * [ | + | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] |
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
| + | |||
| + | :[[File:MSK_Profile-Wiki_Announcement-2.PNG|700px|link=Profiles]] | ||
| + | |||
==Meetings== | ==Meetings== | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| − | *[[Media: | + | *[[Media:2020_09-22_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 22, 2020]] |
| − | *[[Media: | + | *[[Media:2020_07-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 28, 2020]] |
| − | *[[Media: | + | *[[Media:2020_06-23_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 23, 2020]] |
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
==Working Documents== | ==Working Documents== | ||
| + | *[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx| QIBA MSK Profile 2020-01-28:]] ''MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease'' | ||
==Statistical Reference Documents== | ==Statistical Reference Documents== | ||
Revision as of 16:03, 27 October 2020
- Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
- RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease